无 KM 图
入排:排除
图源:开放图源暂不可得
入排置信度 0.96
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.
Y Pointreau, A Larnaudie, X S Sun, F Rolland, P Boisselier, Y Tao, C Hugo, J Bourhis
Radiother Oncol 219 111479
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要
摘要
XXL was a placebo-controlled phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit). Following the unfavorable outcomes of Trilynx [1], XXL the trial was prematurely discontinued after the enrollment of 19 patients and subsequently unblinded; the safety analysis then revealed an increase in treatment-related deaths with xevinapant.
KM 提取结果
0 个 Figure · 0 个 KM 面板